Despite increased spending, the breast cancer detection rate and stage did not change, according to a new JNCI study.
Medicare's mammography costs increased by almost 50% over a 7-year period while the breast cancer detection rate and stage at diagnosis did not change, a 270,000-patient study showed.
Annual Medicare spending rose from $666 million during 2001 to 2002, to $962 million in 2008 to 2009, according to Cary P. Gross, MD, of Yale University, and colleagues. The number of women screened and detection rates for early-stage disease were similar during the two time periods.
The rise in cost coincided with widespread transition from plain-film to more expensive digital mammography, they reported online in the Journal of the National Cancer Institute.
"I view this as important preliminary data suggesting there has been no improvement whatsoever [in detection rates]," Gross told MedPage Today. "As far as why there was no improvement, it's either because the new technology was not more effective or maybe we just need longer follow-up time, and only time will tell."
Read the original report here: http://bit.ly/1qQh4p4
Source: medpageToday
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More